Items Tagged ‘inhibitor of cyclin-dependent kinases’

March 12, 2018

FDA Approval for Verzenio™ as Initial Treatment for Advanced Breast Cancer

By

CancerConnect News: The U.S. Food and Drug Administration (FDA) has approved VerzenioTM (abemaciclib) in combination with an aromatase inhibitor (AI) as initial endocrine-based therapy for the treatment of postmenopausal women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced or metastatic breast cancer. About VerzenioTM Verzenio is an inhibitor of cyclin-dependent kinases […]

View full entry

Tags: 4 & 6, Breast Cancer, CDK, inhibitor of cyclin-dependent kinases, News, Verzenio